What s New in Type 1 and Type 2 Diabetes? Updates from 2013 CDA CPGs and Advancements in Insulin Therapy
|
|
- Hector Webster
- 5 years ago
- Views:
Transcription
1 What s New in Type 1 and Type 2 Diabetes? Updates from 2013 CDA CPGs and Advancements in Insulin Therapy 2013 Rocky Mountain/ACP Internal Medicine Conference November 15, 2013 David C.W. Lau, MD, PhD, FRCPC Depts. of Medicine, Biochem. & Molec. Biol. Julia McFarlane Diabetes Research Centre Libin Cardiovascular Institute of Alberta University of Calgary dcwlau@ucalgary.ca
2 Research funding: Disclosures: David C. W. Lau AHFMR, Alberta Cancer Board, CIHR, AstraZeneca, Boehringer- Ingelheim, BMS, Eli Lilly, Novo Nordisk, Pfizer, sanofi Consultant or advisory board member: Abbott, Allergan, Amgen, AstraZeneca, Bayer, Boehringer- Ingelheim, BMS, Eli Lilly, Merck, Novartis, Novo Nordisk, Pfizer, Roche, sanofi and Valeant Speaker bureau: CDA, HSFC, AstraZeneca, Abbott, Bayer, Boehringer-Ingelheim, BMS, Eli Lilly, Merck, Novo Nordisk, sanofi and Valeant Some slides are selected from accredited CHE programs sponsored by CDA and Novo Nordisk
3 Learning objectives Having completed this case-based program you will: 1. Understand key treatment-related updates from the Canadian Diabetes Association 2013 guidelines 2. Evaluate barriers to optimal glycemic control and assess the role and proper use of current insulins 3. Describe the efficacy and safety of emerging insulin options for the management of diabetes
4 Diabetes is a global disease! Estimated global prevalence of diabetes 151 million 366 million 552 million International Diabetes Federation. IDF Diabetes Atlas. Fifth Edition. 2011
5 Public Health Agency of Canada, Diabetes in Canada. Ottawa, 2011 Diabetes Prevalence Rates in Canada, 2008/09 Canada 6.8%, N=2,359,252 Age- and sex-adjusted diabetes prevalence will increase by 40% within the next 10 years, from 6.8% in a population to 9.9% or 3.4 million in 2020!
6 UKPDS: Legacy Effect of Earlier Glucose Control After median 8.5 years post-trial follow-up Aggregate Endpoint Any diabetes related endpoint RRR: 12% 9% P: Microvascular disease RRR: 25% 24% P: Myocardial infarction RRR: 16% 15% P: All-cause mortality RRR: 6% 13% P: guidelines.diabetes.ca BANTING ( ) diabetes.ca Copyright 2013 Canadian Diabetes Association Holman R, et al. N Engl J Med 2008;359:
7 Questions to Address What should the A1C be for most people and why? Who should we be more aggressive with and why? Who should we be less aggressive with and why? CDA CPGs Can J Diabetes 2013;37:S31-S34 guidelines.diabetes.ca BANTING ( ) diabetes.ca Copyright 2013 Canadian Diabetes Association
8 Individualizing A1C Targets 2013 Consider % if: which must be balanced against the risk of hypoglycemia guidelines.diabetes.ca BANTING ( ) diabetes.ca Copyright 2013 Canadian Diabetes Association
9 To Achieve A1C 7.0% 2013 A1C (%) Preprandial PG (mmol/l) 2-h postprandial PG (mmol/l) For most patients (5-8 if A1C not at target) CDA CPGs Can J Diabetes 2013;37:S31-S34 guidelines.diabetes.ca BANTING ( ) diabetes.ca Copyright 2013 Canadian Diabetes Association
10 Insulin Therapy in Type 1 Diabetes BASAL BOLUS REGIMEN Bolus insulin at meal times + basal insulin once or twice a day OR CONTINUOUS SUBCUTANEOUS INSULIN INFUSION Insulin pump therapy with continuous subcutaneous infusion of insulin via a catheter guidelines.diabetes.ca BANTING ( ) diabetes.ca Copyright 2013 Canadian Diabetes Association
11 AT DIAGNOSIS OF TYPE 2 DIABETES L I F E S T Y L E Start lifestyle intervention (nutrition therapy and physical activity) +/- Metformin A1C <8.5% If not at glycemic target (2-3 mos) Start / Increase metformin A1C 8.5% Start metformin immediately Consider initial combination with another antihyperglycemic agent If not at glycemic targets Add an agent best suited to the individual: Patient Characteristics Degree of hyperglycemia Risk of hypoglycemia Overweight or obesity Comorbidities (renal, cardiac, hepatic) Preferences & access to treatment Other Symptomatic hyperglycemia with metabolic decompensation Agent Characteristics BG lowering efficacy and durability Risk of inducing hypoglycemia Effect on weight Contraindications & side-effects Cost and coverage Other Initiate insulin +/- metformin 2013 guidelines.diabetes.ca BANTING ( ) diabetes.ca Copyright 2013 Canadian Diabetes Association See next page
12 From prior page L I F E S T Y L E If not at glycemic target Add another agent from a different class Add/Intensify insulin regimen 2013 Make timely adjustments to attain target A1C within 3-6 months guidelines.diabetes.ca BANTING ( ) diabetes.ca Copyright 2013 Canadian Diabetes Association
13 2013 CPG: Drug Therapy for Type 2 Diabetes Add an agent best suited to the individual (agents listed in alphabetical order): Class Relative A1C Lowering Hypoglycemia Weight Other therapeutic considerations Cost -glucosidase inhibitor (acarbose) Rare Neutral to Improved postprandial control, GI sideeffects $$ Incretin agents: DPP-4 Inhibitors GLP-1 receptor agonists to Rare Rare Neutral to GI side-effects $$$ $$$$ Insulin Yes No dose ceiling, flexible regimens $-$$$$ Insulin secretagogue: Meglitinide Sulfonylurea Yes* Yes *Less hypoglycemia in context of missed meals but usually requires TID to QID dosing Gliclazide and glimepiride associated with less hypoglycemia than glyburide Thiazolidinediones Rare CHF, edema, fractures, rare bladder cancer (pioglitazone), cardiovascular controversy (rosiglitazone), 6-12 weeks required for maximal effect $$ $ $$ Weight loss agent (orlistat) None GI side effects $$$ CDA CPGs. Can J Diabetes 2013;37: S61-S68
14 Change in A1C from baseline to 26 weeks (%) Glucose Lowering Therapy in Diabetes: A1C Reduction by Baseline A1C % >7.5% - 8.0% >8.0% to 8.5% >8.5% to 9.0% >9.0% Diabetes disease progression * ** Liraglutide Sitagliptin Glimepiride Rosiglitazone Exenatide Glargine ** ** ** ** ** * * **** *** * *p<0.05, **p<0.01, ***p<0.001, ****p< vs. liraglutide 1.8 mg; Henry RR, et al. Endocr Pract 2011;17(6):907
15 Change in Glycated Hemoglobin (%) DPP-4 Inhibitors: A1C Lowering Efficacy in Relation to Baseline A1C Levels Sitagliptin Vildagliptin Saxagliptin Linagliptin Alogliptin Mono Rx Initial Combo Baseline Glycated Hemoglobin (%) Deacon CF. Diabetes Obes Metab 2011;13:7 18
16 Changes in A1C and Body Weight: Liraglutide, Exenatide and Sitagliptin = LEAD-6 = Lira-DPP-4 = LEAD-6 = Lira-DPP-4 Adapted from Niswender K et al, Diab Obes Metab 2012 doi: /j x
17 SAVOR TIMI-53: Study Design ~16,500 patients Documented T2DM and established CVD (secondary prevention) or multiple CV risk factors (primary prevention) SAXAGLIPTIN 2.5 or 5 mg/d RANDOMIZE 1:1 DOUBLE BLIND Dosing based on egfr All other diabetes therapy per treating doctors PLACEBO DURATION: Event driven; 1,040 events required to power the study Follow up visits Q6 months Final Visit PRIMARY ENDPOINT: CV death, non-fatal MI, non-fatal ischemic stroke Scirica BM, et al. Am Heart J 2011; 162:818-25
18 Kaplan Meier Rates of the Primary and Secondary End Points Scirica BM et al. N Engl J Med DOI: /NEJMoa
19 SAVOR-TIMI 53: Individual Components of the Composite Endpoints Saxagliptin Placebo n (%)* n (%)* Efficacy endpoint (N = 8,280) (N = 8,212) HR (95% CI) P value CV death 269 (3.2) 260 (2.9) 1.03 ( ) 0.72 MI 265 (3.2) 278 (3.4) 0.95 ( ) 0.52 Ischemic stroke 157 (1.9) 141 (1.7) 1.11 ( ) 0.38 Hosp for UA 97 (1.2) 81 (1.0) 1.19 ( ) 0.24 Hosp for HF 289 (3.5) 228 (2.8) 1.27 ( ) Hosp for coronary revasc. 423 (5.2) 459 (5.6) 0.91 ( ) 0.18 *K-M event rates are presented after 2 yrs. Scirica BM, et al. N Engl J Med /NEJMoa
20 Pancreatitis and Pancreatic Cancer Any pancreatitis Acute (definite or possible) Acute (definite) Acute (possible) Saxagliptin n (%) (N = 8,280) 24 (0.3) 22 (0.3) 17 (0.2) 6 (0.07) Placebo n (%) (N = 8,212) P value* 21 (0.3) 16 (0.2) 9 (0.1) 7 (0.09) Pancreatic cancer All cases of pancreatitis were independently adjudicated *Chi-square test or exact test. Patients may have had more than 1 type of event. Scirica BM, et al. N Engl J Med /NEJMoa
21 Cardiovascular Safety of Sulfonylureas: Meta analysis of Randomized Clinical Trials Monami M, et al. Diab Obes Metab 2013;15:938-53
22 CV Outcome Trials of Glucose-lowering Drugs SAVOR-TIMI53 Saxagliptin Sept 2013 N=16,492 ACE Acarbose N = 7,500 July 2014 CAROLINA Linagliptin N = 6,000 Sep 2018 : DPP-4i : GLP-1 EXAMINE Alogliptin Sept 2013 N=5,380 TECOS Sitagliptin Dec 2014 N=14,00 CARMELINA Linagliptin N = 8,300 Jan ELIXA Lixisenatide N = 6,000 Jan 2015 LEADER Liraglutide N = 9,340 Oct 2015 EXSCEL Exenatide N = 9,500 Mar 2017 REWIND Dulaglutide N = 9,622 Apr 2019 SUSTAIN-6 Semaglutide N = 3,260 Jan 2016
23 Serum Insulin Level Basal-bolus Insulin Therapy Time Human Basal: Humulin-N, Novolin ge NPH Analogue Basal: Lantus, Levemir Human Bolus: Humulin-R, Novolin ge Toronto Analogue Bolus: Apidra, Humalog, NovoRapid guidelines.diabetes.ca BANTING ( ) diabetes.ca Copyright 2013 Canadian Diabetes Association
24 Serum Insulin Level Pre-mixed Insulin Therapy Time Human Premixed: Humulin 30/70, Novolin ge 30/70 Analogue Premixed: Humalog Mix25, NovoMix 30 guidelines.diabetes.ca BANTING ( ) diabetes.ca Copyright 2013 Canadian Diabetes Association
25 Types of Insulin for Use in T1DM Insulin Type (trade name) Onset Peak Duration Bolus (prandial) Insulins Rapid-acting insulin analogues (clear): Insulin aspart (NovoRapid ) Insulin glulisine (Apidra ) Insulin lispro (Humalog ) min min min h h 1-2 h 3-5 h 3-5 h h Short-acting insulins (clear): Insulin regular (Humulin -R) Insulin regular (Novolin getoronto) 30 min 2-3 h 6.5 h Basal Insulins Intermediate-acting insulins (cloudy): Insulin NPH (Humulin -N) Insulin NPH (Novolin ge NPH) Long-acting basal insulin analogues (clear) Insulin detemir (Levemir ) Insulin glargine (Lantus ) 1-3 h 5-8 h Up to 18 h 90 min Not applicable Up to 24 h (glargine 24 h, detemir h) guidelines.diabetes.ca BANTING ( ) diabetes.ca Copyright 2013 Canadian Diabetes Association
26 Types of Insulin (continued) Premixed Insulins Insulin Type (trade name) Premixed regular insulin NPH (cloudy): 30% insulin regular/ 70% insulin NPH (Humulin 30/70) 30% insulin regular/ 70% insulin NPH (Novolin ge 30/70) 40% insulin regular/ 60% insulin NPH (Novolin ge 40/60) 50% insulin regular/ 50% insulin NPH (Novolin ge 50/50) Time action profile A single vial or cartridge contains a fixed ratio of insulin (% of rapid-acting or short-acting insulin to % of intermediate-acting insulin) Premixed insulin analogues (cloudy): 30% Insulin aspart/70% insulin aspart protamine crystals (NovoMix 30) 25% insulin lispro / 75% insulin lispro protamine (Humalog Mix25 ) 50% insulin lispro / 50% insulin lispro protamine (Humalog Mix50 ) guidelines.diabetes.ca BANTING ( ) diabetes.ca Copyright 2013 Canadian Diabetes Association
27 Studies of Pump Therapy Alone: Forest Plot of Pump Therapy vs. MDI Trials, A1C Outcomes Misso ML et al. Cochrane Database Syst Rev 2010 (1)
28 Recommendations To achieve glycemic targets in adults with type 1 diabetes, basalbolus insulin regimens or the use of CSII as part of an intensive diabetes management regimen should be used [Grade A, Level 1A] 2. Rapid-acting insulin analogues, in combination with adequate basal insulin, should be used instead of regular insulin, to minimize the occurrence of hypoglycemia, improve A1C [Grade B, Level 2] and achieve postprandial glucose targets [Grade B, Level 2] 3. Rapid acting insulin analogues (aspart or lispro) should be used with CSII in adults with type 1 diabetes [Grade B, Level 2] CDA CPGs. Can J Diabetes 2013;37:S56-60 guidelines.diabetes.ca BANTING ( ) diabetes.ca Copyright 2013 Canadian Diabetes Association
29 Recommendations 4 and 5 4. A long-acting insulin analogue (detemir, glargine) may be used as the basal insulin [Grade B, Level 2] to reduce the risk of hypoglycemia [Grade B, Level 2], for detemir; [Grade C, Level 3], for glargine], including nocturnal hypoglycemia [(Grade B, Level 2), for detemir ;(Grade D, Consensus), for glargine]. 5. All individuals with type 1 diabetes should be counseled about the risk and prevention of insulin-induced hypoglycemia, and risk factors for severe hypoglycemia should be identified and addressed [Grade D, Consensus] CDA CPGs. Can J Diabetes 2013;37:S56-60 guidelines.diabetes.ca BANTING ( ) diabetes.ca Copyright 2013 Canadian Diabetes Association
30 Diabetes Rx in Canada (DM SCAN) Survey of 479 Primary care physicians across Canada 5,123 patients with type 2 diabetes seen on November 14 th, 2012 (World Diabetes Day) Mean age 64 years Mean duration of DM = 9.2 years Mean A1C 7.4% Mean LDL-C 2.1 mmol/l Mean blood pressure = 128/75 mmhg Leiter LA et al. Can J Diabetes 2013;37:82-89
31 Diabetes Rx in Canada (DM SCAN) Many patients NOT achieving targets: A1C 7.0% was met by 50% LDL-C 2.0 mmol/l by 57% BP <130/80 mmhg by 36% Composite triple target only by 13% of patients Higher use of insulin compared to previous surveys (40% versus 12%) Longer duration of DM compared to previous surveys Leiter LA et al Can J Diabetes 2013;37:82-89
32 β-cell function (%, HOMA) Matching Diabetes Therapy to Disease Progression nd or 3 rd OAD(s) OD basal insulin Metformin Diet and exercise Years from diagnosis 8 HOMA, Homeostasis Model Assessment; OAD, oral antihyperglycemic drug; OD, once daily
33 Case study Insulin initiation History Lucie is aged 57 years She has been diagnosed with type 2 diabetes for 9 years She works full-time in a bank and has an erratic meal schedule She is concerned about her weight and her glucose control
34 Case study Insulin initiation Medications: Metformin 1000 bid Glyburide 10 bid Sitagliptin 100 mg od Quinipril 40 mg od Pravastatin 40 mg od - Tried a TZD but did not tolerate edema
35 Case study Insulin initiation Vital signs and laboratory parameters at diagnosis Weight 91 kg (200 Lbs) Waist circumference 92 cm (36.2 inches) BMI 31.4 kg/m 2 (obese, class I) A1C 9.1%
36 What are the main reasons why your patients are reluctant to initiate insulin? 1. Fear of needles 2. Fear of weight gain 3. Fear diabetes is worsening 4. Insulin causes complications 5. Other
37 Resistance to Insulin Therapy Fear of needles and injections Fear of complications, particularly hypoglycemia Fear of weight gain Inconvenience: More time-consuming Inadequate support and/or resources: Lack of information Cost Sense of failure Poor self confidence Fear diabetes is worsening Belief that insulin causes complications Meece J. The Diabetes Educator 2006; 32:9S 18S Go to Peyrot M et al. Diabetes Care 2005; 28: Hunt LM et al. Diabetes Care 1997; 20:
38 Lucie s SMBG diary (mmol/l) Date Pre-breakfast Pre- lunch Pre-supper Bedtime Sunday Monday Tuesday 11.2 Wednesday 8.6 Thursday 10.9 Friday Saturday
39 Adapted from Canadian Diabetes Association. Canadian Journal of Diabetes 2008; 32:Appendix 3. Examples of insulin initiation regimens Example A Example B Bedtime basal + antihyperglycemic agents Premixed insulin + Antihyperglycmic agents Most common start Example C Prandial insulin +/- Basal (multiple injections or prandial insulin only or continuous infusion) and antihyperglycemic agents
40 Basal Insulins Insulin type (trade name) Onset Peak Duration Intermediate-acting Humulin -N Novolin ge NPH Long-acting basal analogues 1 3 hrs 5 8 hrs Up to 18 hrs Insulin detemir (Levemir ) Insulin glargine (Lantus ) 90 min Not applicable Up to 24 hrs CDA CPGs. Can J Diabetes 2013;37:S56-S60
41 Basal insulins Insulin type (trade name) Onset Peak Duration Intermediate-acting Humulin -N Novolin ge NPH Long-acting basal analogues Insulin detemir (Levemir ) Insulin glargine (Lantus ) 1 3 hrs 5 8 hrs Up to min Not applicable Up to 24 hrs Long-acting basal analogues reduce the risk of overnight hypoglycemia by ~20% CDA CPGs. Can J Diabetes 2013;37:S56-S60
42 Example A Bedtime basal and antihyperglycemic agents Goal: Target fasting glucose ( mmol/l) ( mg/dl) Initiate basal insulin 5-10 units at bedtime Titrate up to 1 unit/day until target reached Patients should self-monitor at least once daily (fasting) Do not increase dose and consider decreasing dose if: Two hypos in 1 week or One nighttime hypo If daytime hypos occur, insulin secretagogues may need to be reduced Continue oral agents ( if on TZD consider stopping or close survellence CDA CPGs. Can J Diabetes 2013;37:S200
43 Basal Analogues Have Similar 24-hour Glucose Profile, Similar Dose Section 1.3 How How to initiate to initiate insulin insulin? 24 hour glucose profile for insulins detemir and glargine King AB. Diabetes Obes Metab 2009;11:69 71
44 Case study Insulin initiation Insulin is initiated with a long-acting insulin analogue (NPH could be used if cost was an issue) 10 U at bedtime was initiated She was asked to titrate up by 1 Unit every night until am glucose was less than 7.0 mmol/l (125 mg/dl)
45 Lucie s SMBG diary: 3 weeks later 22 U of Basal insulin at bedtime Date Pre-breakfast Pre-lunch Pre-supper Bedtime Sunday Monday 7.2 Tuesday Wednesday Thursday Friday 7.3 Saturday
46 Lucie s SMBG diary: 5 weeks later 32 U of Basal insulin at bedtime Date Pre-breakfast Pre-lunch Pre-Supper Bedtime Sunday Monday 6.2 Tuesday Wednesday Thursday Friday 6.3 Saturday
47 Lucie has hypoglycemic symptoms in the late am What would you like to do for Lucie now? Glyburide may be causing hypoglycemia in the late am Glyburide likely should be reduced or changed If discontinued, glucose levels may rise throughout the day Dietary changes are another option Glyburide was discontinued and insulin dosage increased
48 Lucie s SMBG diary: 18 weeks later 44 U of Basal insulin at bedtime, A1C = 7.2% Date Pre-breakfast Pre- lunch Pre-supper Bedtime Sunday Monday 6.2 Tuesday Wednesday Thursday Friday 6.3 Saturday
49 Premixed insulins Insulin type (trade name) Premixed regular insulin NPH Humulin 30/70, (70/30) Novolin ge 30/70, 40/60, 50/50, (70/30) (60/40) Premixed insulin analogues Biphasic insulin aspart (NovoMix 30)(Novolog 70/30) Insulin lispro/lispro protamine (Humalog Mix25 and Mix50 )(Humalog Mix 75/25) Notes A single vial or cartridge contains a fixed ratio of insulin (% rapid-acting or short-acting insulin to % intermediate-acting insulin) Adapted from Canadian Diabetes Association. Canadian Journal of Diabetes 2008; 32:S47 & S57.
50 Prandial (Bolus) Insulins Insulin type (trade name) Onset Peak Duration Rapid-acting insulin analogues Insulin aspart (NovoRapid ) min hrs 3 5 hrs Insulin glulisine (Apidra ) min hrs 3 5 hrs Insulin lispro (Humalog ) min 1 2 hrs hrs Short-acting insulins Humulin -R Novolin ge Toronto 30 min 2 3 hrs 6.5 hrs Analogues should be considered instead of regular insulin (CDA Guidelines) CDA CPGs. Can J Diabetes 2013;37:S56-S60
51 N Engl J Med 2009:361: Published online October 22, 2009
52 4T Study: Insulin Initiation 708 patients starting insulin Inadequate glycemic control on metformin and SU Individuals randomized to 3 different regimes 1. pre-mixed biphasic insulin aspart (NovoMix 30) 2. prandial insulin aspart (NovoRapid per meal) 3. basal insulin detemir (Levemir at bed or BID if required) Holman RR et al. N Engl J Med 2009;361:
53 A1C change (%) Reductions in A1C Seen With All Analogue Intensification Regimens Premix insulin analogue* start Mealtime insulin analogue start Basal insulin analogue start Intensification after initial insulin treatment failure: * Premix insulin analogue bid + mealtime insulin at lunch Mealtime insulin analogue tid + basal insulin analogue at bedtime Basal insulin analogue at bedtime + mealtime insulin tid P=0.28 versus mealtime insulin. P=0.67 versus basal insulin analogue. P=0.52 versus premix insulin analogue. Adapted from Holman RR et al. New Engl J Med 2007; 357: Holman RR et al. New Engl J Med 2009; 361:
54 4T Study: Insulin Initiation - Results Mean A1C levels achieved were similar: 7.1% biphasic, 6.8% prandial, 6.9% basal Hypoglycemia rates (per patient per year) lowest in basal group (1.7%), biphasic group (3.0%), prandial group (5.7%) Mean weight gain highest in the prandial group The authors concluded that basal insulin had better control, less hypoglycemia, and less weight gain Holman RR et al. New Engl J Med 2009; 361:
55 Patients (%) Glargine vs NPH: less hypoglycemia Type 2 DM Patients experiencing 1 episode of hypoglycemia * p=0.022 Insulin Glargine (n=264) NPH Insulin (n=270) p= p= All Symptomatic Nocturnal Type of hypoglycemia Severe * Symptomatic, nocturnal or severe hypoglycemia confirmed by BG level <2mmol/L (month 2 to endpoint). Ratner RE et al. Diabetes Care 2000;23:
56 NNT to Avoid One Nocturnal Hypoglycemic Episode: Glargine versus NPH Symptomatic (<3.9): NNT = 8 (p<0.001) Symptomatic (<2.0): NNT = 107 (p=0.002) Severe: NNT = 112 (p=0.047) Fritsche A et al. Diab Obes Metab 2010;12:
57 Nocturnal hypoglycaemia (number of events) Levemir versus NPH: Less Nocturnal Hypoglycemia RR=45% ** 349 Insulin detemir (n=237) NPH insulin (n=238) * ** All Major Minor confirmed Symptomatic unconfirmed **p<0.001 *p<0.01 Type of hypoglycemia Hermansen K et al. Diabetes Care 2006;29:
58 Key summary points Algorithms and therapies for initiating insulin There are many types of insulin available The simplest way to initiate insulin is to start with a basal insulin: 5-10 units at bedtime Titrate up to 1 unit/day until target reached Long-acting analogues reduce risk of hypoglycemia versus NPH For consideration as the disease progresses, adding an insulin to manage mealtime needs may become necessary CDA CPGs. Can J Diabetes 2013;37:S56-S60
59 New Ultra-longacting Basal Insulin Insulin Degludec
60 Molecular size determines rate of subcutaneous absorption the idea behind insulin degludec Brange et al. Diabetes Care 1990;13:923 54
61 Insulin Degludec: Design
62 Insulin degludec: immediately after injection Jonassen I et al. Pharm Res 2012;29:
63 Insulin degludec: slow release following injection Jonassen I et al. Pharm Res 2012;29:
64 Insulin degludec: slow release following injection Jonassen I et al. Pharm Res 2012;29:
65 Insulin degludec: slow release following injection Jonassen I et al. Pharm Res 2012;29:
66 Insulin Degludec vs. Glargine: Efficacy and Hypoglycemia in DM1 Heller S et al. Lancet 2012;379:
67 Insulin Degludec vs. Glargine: Efficacy and Hypoglycemia in DM2 Garber AJ et al. Lancet 2012;379:
68 Insulin Degludec: Summary Through the formation of multihexamer chains of insulin in subcutaneous depots, degludec has an extra long duration of action (half-life >25 hours and activity > 40 hours) Insulin degludec effectively improves A1C and is noninferior to insulin glargine in bolus and basal-bolus therapy in both type 1 and type 2 diabetes Insulin degludec results in significantly less risk of hypoglycemia than insulin glargine 20% less risk of overall confirmed hypoglycemia 25% less risk of nocturnal hypoglycemia Degludec improves the quality of life of people with diabetes who require insulin therapy Heller S et al. Lancet 2012;379: Garber AJ et al. Lancet 2012;379:
69 Key Messages on Insulin Therapy Individuals must strive for self management of their diabetes Self management of insulin: individuals need to be proactive and less reactive Need to adjust insulin doses to reach the next upcoming target Patients should ask themselves: should I take more or less insulin with this injection?
70 Glycemic Management of Diabetes 2013 CDA guidelines recommend that glycemic management should be individualized, aiming for A1C 7% for most people Basal-bolus insulin therapy are the insulin regimens of choice for all adults with type 1 diabetes Metformin is the initial choice for type 2 diabetes, with additional antihyperglycemic agents selected on the basis of matching individuals with drug characteristics Metformin, incretin-based therapies and acarbose, are not associated with adverse CV outcomes Analogues should be considered instead of human insulin to improve A1C while minimizing the occurrence of hypoglycemia All individuals with diabetes should be counseled about the risk, prevention and treatment of hypoglycemia CDA CPGs. Can J Diabetes 2013;37:S31-S34
71 THANK YOU Questions?
INSULIN 101: When, How and What
INSULIN 101: When, How and What Alice YY Cheng @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form
More informationIn-Hospital Management of Diabetes. Dr Benjamin Schiff Assistant Professor McGill University
In-Hospital Management of Diabetes Dr Benjamin Schiff Assistant Professor McGill University No conflict of interest to declare CLINICAL SCENARIO 62 y/o male with hx of DM 2, COPD, and HT is admitted with
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationUpdate on Insulin-based Agents for T2D. Harry Jiménez MD, FACE
Update on Insulin-based Agents for T2D Harry Jiménez MD, FACE Harry Jiménez MD, FACE Has received honorarium as Speaker and/or Consultant for the following pharmaceutical companies: Eli Lilly Merck Boehringer
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationTable 1. Antihyperglycemic agents for use in type 2 diabetes
Table 1. Antihyperglycemic agents for use in type 2 diabetes DRUG IN ALPHA-GLUCOSIDASE INHIBITOR: inhibits pancreatic alpha-amyle and intestinal alpha-glucoside Acarbose (Glucobay) 0.6% Negligible Not
More informationDIABETES DEBATE - IS NEW BETTER?
DIABETES DEBATE - IS NEW BETTER? WHAT MEDICATION CLASS AFTER METFORMIN TO CONTROL BLOOD SUGAR Dr. Lydia Hatcher, MD, CCFP, FCFP, CHE, D-CAPM Associate Clinical Professor of Family Medicine, McMaster Chief
More informationCanadian Diabetes Association 2013
Spring 2014 Canadian Diabetes Association 2013 clinical practice guidelines - Do claims data align to the guidelines? Canadian Diabetes Association 2013 clinical practice guidelines - Do claims data align
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationQuick Reference Guide
2013 Clinical Practice Guidelines Quick Reference Guide (Updated November 2016) 416569-16 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Copyright 2016 Canadian Diabetes Association SCREENING
More informationManaging Perioperative Diabetes What s new? Kathryn A. Myers MD FRCPC Chair Chief Division of GIM Professor of Medicine Western University
Managing Perioperative Diabetes What s new? Kathryn A. Myers MD FRCPC Chair Chief Division of GIM Professor of Medicine Western University Objectives: By the end of this session, you will be able to: Identify
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationUKPDS: Over Time, Need for Exogenous Insulin Increases
UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin
More informationVery Practical Tips for Managing Type 2 Diabetes
Very Practical Tips for Managing Type 2 Diabetes Jean-François Yale, MD, FRCPC McGill University Health Centre, Montreal, Canada Jean-francois.yale@mcgill.ca www.dryale.ca OBJECTIVES DISCLOSURES The participant
More informationTips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital
Tips and Tricks for Starting and Adjusting Insulin MC MacSween The Moncton Hospital Progression of type 2 diabetes Beta cell apoptosis Natural History of Type 2 Diabetes The Burden of Treatment Failure
More informationObjectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors
No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable
More informationTABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations
177 TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary Coverage Indication for use with: INSULIN THERAPY NS NB NL PE ADULTS PEDIATRICS PREGNANCY BOLUS
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationInsulin 301: Case, after case, after case
Insulin 301: Case, after case, after case Learning objectives By the end of this session, you will be able to : 1. List the 3 types of insulin, 3 insulin regimens and pros/cons of each 2. Select the regimen
More informationTABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations
177 TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Choosing the Right Agent for your Patient with diabetes: Individualizing type 2 diabetes management in light of the expanding therapies
More informationGuide to Starting and Adjusting Insulin for Type 2 Diabetes*
Guide to Starting and Adjusting Insulin for Type 2 Diabetes* www.cadth.ca * Adapted from Guide to Starting and Adjusting Insulin for Type 2 Diabetes, 2008 International Diabetes Center, Minneapolis, MN.
More informationNew Drug Evaluation: Insulin degludec/aspart, subcutaneous injection
New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection Date of Review: March 2016 End Date of Literature Search: November 11, 2015 Generic Name: Insulin degludec and insulin aspart Brand
More informationAntihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014
Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they
More informationDiabetic Management of the Cardiac Patient
Diabetic Management of the Cardiac Patient Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Disclosures Grants/Research Support:
More informationCanadian Journal of Diabetes
Can J Diabetes 42 (2018) S88 S103 Contents lists available at ScienceDirect Canadian Journal of Diabetes journal homepage: www.canadianjournalofdiabetes.com 2018 Clinical Practice Guidelines Pharmacologic
More informationWhat the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin
Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationInsulin Prior Authorization with optional Quantity Limit Program Summary
Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)
More informationCASES DR TINA KADER MCGILL JGH; LMC CVPH CDE
CASES DR TINA KADER MCGILL JGH; LMC CVPH CDE Faculty/Presenter Disclosure Faculty/Presenter: tina kader Relationships with commercial interests: Grants/research support: BI; Sanofi Speaker s bureau/honoraria:
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationBeyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM
Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning
More informationPreventing Serious Health Consequences of Type 2 Diabetes
Preventing Serious Health Consequences of Type 2 Diabetes The Evidence Hertzel C. Gerstein MD MSc FRCPC Professor and Population Health Institute Chair in Diabetes Research McMaster University and Hamilton
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationQuick Reference Guide
2018 Clinical Practice Guidelines Quick Reference Guide 416569-18 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Screening and diagnosis of type 2 diabetes in adults Assess risk factors for
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More informationLa lezione dei trials di safety cardiovascolare. Edoardo Mannucci
La lezione dei trials di safety cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationMANAGING DIABETES IN 2016 WHAT TO ADD, WHEN AND WHY?
MANAGING DIABETES IN 2016 WHAT TO ADD, WHEN AND WHY? Faculty: Maria Wolfs MD, MHSc, FRCPC Assistant Professor, University of Toronto Staff Endocrinologist, St. Michael's Hospital Relationships with commercial
More informationIndividualizing Care for Patients with Type 2 Diabetes
Individualizing Care for Patients with Type 2 Diabetes Disclosures Speaker: AstraZeneca, Novo Nordisk, BI/Lilly, Valeritas, Takeda Advisor: Tandem Diabetes, Sanofi Objectives Develop individualized approaches
More informationMANAGING DIABETES IN 2017 WHAT TO ADD, WHEN AND WHY? December 8, 2017 Maria Wolfs MD MHSc FRCPC
MANAGING DIABETES IN 2017 WHAT TO ADD, WHEN AND WHY? December 8, 2017 Maria Wolfs MD MHSc FRCPC Faculty Disclosure Faculty: Maria Wolfs MD, MHSc, FRCPC Assistant Professor, University of Toronto Endocrinologist,
More informationInsulin Therapy Management. Insulin Therapy
Insulin Therapy Management Insulin Therapy Contents Insulin and its effect on glycemic control Physiology of insulin secretion Insulin pharmacokinetics and regimens Insulin dose adjustment for pregnancy
More informationBRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH
Insulin Initiation BRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH Disclosures In the past 12 months, I have received speakers honoraria from AstraZeneca, Boehringer Ingelheim,
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationOptimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes
Optimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes Philip Raskin, MD Professor of Medicine The University of Texas, Southwestern Medical Center NAMCP Spring
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationPHARMACISTS INTERACTIVE EDUCATION CASE STUDIES
PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES Disclaimer: The information in this document is not a substitute for clinical judgment in the care of a particular patient. CADTH is not liable for any damages
More informationUpdate on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationNewer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference
Newer Insulins Boca Raton Regional Hospital 15th Annual Internal Medicine Conference Luigi F. Meneghini, MD, MBA Professor of Internal Medicine, UT Southwestern Medical Center Executive Director, Global
More informationPHARMACISTS INTERACTIVE EDUCATION CASE STUDIES
PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES Disclaimer: The information in this document is not a substitute for clinical judgment in the care of a particular patient. CADTH is not liable for any damages
More informationIndividualising Insulin Regimens: Premixed or basal plus/bolus?
Individualising Insulin Regimens: Premixed or basal plus/bolus? Dr. Ted Wu Director, Diabetes Centre, Hospital Sydney, Australia Turkey, April 2015 Centre of Health Professional Education Optimising insulin
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationObjectives 2/13/2013. Figuring out the dose. Sub Optimal Glycemic Control: Moving to the Appropriate Treatment
Sub Optimal Glycemic Control: Moving to the Appropriate Treatment Judy Thomas, MSN, FNP-BC Holt and Walton, Rheumatology and Endocrinology Objectives Upon completion of this session you will be better
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationVascular complications
Vascular complications December 8, 2018 Faculty Disclosure Faculty: Kim Connelly, MBBS, PhD, FRACP Associate Professor of Medicine, University of Toronto Cardiologist, St. Michael s Hospital Relationships
More informationThe Diabetes Guidelines Trek: The Next Generation. Inpatient Diabetes Guidelines. Learning Objectives. Current Inpatient Guidelines
The Diabetes Guidelines Trek: The Next Generation J. Christopher Lynch, PharmD, BCACP Southern Illinois University Edwardsville School of Pharmacy Susan Cornell BS, PharmD, CDE, FAPhA, FAADE Midwestern
More informationGLP-1RA and insulin: friends or foes?
Tresiba Expert Panel Meeting 28/06/2014 GLP-1RA and insulin: friends or foes? Matteo Monami Careggi Teaching Hospital. Florence. Italy Dr Monami has received consultancy and/or speaking fees from: Merck
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationType 2 Diabetes Mellitus Insulin Therapy 2012
Type 2 Diabetes Mellitus Therapy 2012 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Preparations Onset Peak Duration
More informationStarting and Helping People with Type 2 Diabetes on Insulin
Starting and Helping People with Type 2 Diabetes on Insulin Elaine Cooke, BSc(Pharm), RPh, CDE Pharmacist and Certified Diabetes Educator Maple Ridge, BC Objectives After attending this session, participants
More informationNew Therapies for Diabetes Management: Hope or Headache?
New Therapies for Diabetes Management: Hope or Headache? Elizabeth Stephens, MD, FACP PMG- Endocrinology Elizabeth.Stephens@providence.org November 2018 Disclosures None 1 Objectives Discussion of 3 rd
More informationCase Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials
Case Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials Louis Kuritzky MD Clinical Assistant Professor Emeritus Department of Community Health and Family Medicine College of Medicine
More informationQuick Reference Guide
2018 Clinical Practice Guidelines Quick Reference Guide 416569-18 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Screening and Diagnosis Assess risk ANNUALLY if: Family history (First-degree
More informationDu gusts is megl che one. Edoardo Mannucci
Du gusts is megl che one Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer Ingelheim, Eli
More informationMedications for Diabetes
Medications for Diabetes Sweet, but not too sweet Colette Raymond, Pharm D June 15, 2011 Learning Objectives At the end of this presentation you should be able to: Understand the prevalence and types of
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Jessica Conklin, PharmD, PhC, BCACP, CDE, AAHIP Associate Professor, UNM College of Phar macy jeconklin@salud.unm.edu Luis Gonzales, PharmD, PhC UNM
More informationUpdate on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP
Update on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research InsAtute University of Miami Miller School of Medicine
More informationUpdate on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015
Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages
More informationWhat s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital
What s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital Therapy considerations in T2DM Thiazoledinediones DPP IV inhibitors GLP 1 agonists Insulin Type Delivery Horizon scanning
More informationInitiation and Adjustment of Insulin Regimens for Type 2 Diabetes
Types of Insulin Rapid-acting insulin: lispro (Humalog), aspart (NovoRapid), glulisine (Apidra) Regular short-acting insulin: Humulin R, Novolin ge Toronto, Hypurin Regular Basal insulin: NPH (Humulin
More informationUpdate on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy
Update on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy Jerry Meece, BPharm, CDE, FACA, FAADE Director of Clinical Services Plaza Pharmacy and Wellness Center Gainesville,
More informationDisclaimers 22/03/2018. Role of DPP-4 Inhibitors, GLP-1 Agonists, and SGLT-2 Inhibitors in the treatment of Diabetes Mellitus Type 2
Disclaimers Role of DPP-4 Inhibitors, GLP-1 Agonists, and SGLT-2 Inhibitors in the treatment of Diabetes Mellitus Type 2 I have not received money or gifts from medical device companies or from the pharmaceutical
More informationMixed Insulins Pick Me
Mixed Insulins Pick Me Alvin Goo, PharmD Clinical Associate Professor University of Washington School of Pharmacy and Department of Family Medicine Objectives Critically evaluate the evidence comparing
More informationObjectives. Navigating New Insulins. Disclosures. Diabetes: The Stats. Normal Insulin Release Individuals without diabetes. History of Insulin 5/23/17
Objectives Compare and contrast currently available products. Navigating New s Diana Isaacs, PharmD, BCPS, BC-ADM, CDE Clinical Pharmacy Specialist Cleveland Clinic Diabetes Center Determine the factors
More informationThis case study is supported by an educational grant from Abbott.
Program Name: Planning Committee: When and How to Start or Intensify Insulin Therapy in Your Patients with Type 2 Diabetes Alice Cheng, MD, FRCPC Jean-Francois Yale, MD, CSPQ Lori Berard, RN, CDE Sol Stern,
More informationInsulin Basics. Bryan Primary Care Conference May 21, 2016 Shannon Wakeley MD Complete Endocrinology
Insulin Basics Bryan Primary Care Conference May 21, 2016 Shannon Wakeley MD Complete Endocrinology Disclosures Speakers Bureau for Sanofi, Astra Zeneca, Janssen, Boehringer-Ingelheim Objectives Discuss
More informationINSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION
INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION Jaiwant Rangi, MD, FACE Nov 10 th 2018 DISCLOSURES Speaker Novo Nordisk Sanofi-Aventis Boheringer Ingleheim Merck Abbvie Abbott
More informationINSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE
INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE OBJECTIVES DESCRIBE INSULIN, INCLUDING WHERE IT COMES FROM AND WHAT IT DOES STATE THAT
More information9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends
+ Diabetes Update: Guidelines, Treatment Options & Trends Melissa Max, PharmD, BC-ADM, CDE Assistant Professor of Pharmacy Practice Harding University College of Pharmacy + Disclosure Conflicts Of Interest
More informationType 2 Diabetes Mellitus 2011
2011 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetes Mellitus Diagnosis 2011 Diabetes Mellitus Fasting Glucose
More informationDiabetes and Chronic Kidney Disease DR. JEREMY GILBERT, MD FRCPC ASSISTANT PROFESSOR, U OF T
Diabetes and Chronic Kidney Disease DR. JEREMY GILBERT, MD FRCPC ASSISTANT PROFESSOR, U OF T Objectives Recognize the impact that CKD has on diabetes management Review the current Canadian Diabetes Association
More informationNew basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011
New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011 Presenter Disclosure I have received the following
More informationCADTH Optimal use report
Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé CADTH Optimal use report Volume 3, Issue 1D July 2013 Optimal Use Recommendations
More informationAchieving and maintaining good glycemic control is an
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,
More informationTerapia con agonisti GLP1 e outcome cardiovascolare. Edoardo Mannucci
Terapia con agonisti GLP e outcome cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca,
More informationFaculty. Timothy S. Reid, MD (Co-Chair, Presenter) Medical Director Mercy Diabetes Center Janesville, WI
Activity Overview In this case-based webcast, meet Jackie, a 62-year-old woman with type 2 diabetes. Her glycated hemoglobin (HbA1C) is 9.2%, and she is taking 2 oral agents and basal insulin; however,
More informationNavigating the New Options for the Management of Type 2 Diabetes
Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of
More informationJulie White, MS Administrative Director Boston University School of Medicine Continuing Medical Education
MENTOR QI Diabetes Performance Improvement Initiative, Getting Patients to Goal in Glycemic Control: Current Data Julie White, MS Administrative Director Boston University School of Medicine Continuing
More informationUpdate on Cardiovascular Outcome Trials in Diabetes. Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013
Update on Cardiovascular Outcome Trials in Diabetes Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013 Residual Vascular Risk in People with Diabetes 2 Analyses based on 530,083 participants
More information7/8/2016. Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine
Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine Participation in investigator initiated clinical research supported by: Merck Boehringer Ingelheim Novo Nordisk Astra Zeneca
More information